; and (B) recommendations for improving such techniques. (4) An evaluation on the effectiveness of treatments for prostate cancer and the development of recommendations for new treatments, including new biological agents. (5) With respect to prostate cancer, an evaluation on the effectiveness of clinical practice guidelines and the development of recommendations to improve such guidelines. (6) The development of recommendations to improve clinical pathways in private and government-operated medical systems, including screening and diagnosis and information on informed and shared decision making. (7) The development of recommendations for research investigation methods for improving the quality of life of individuals who have survived with prostate cancer. (8) With respect to prostate cancer, an evaluation on the effectiveness of information and education programs for health care professionals and the public. (9) With respect to screening and clinical trial enrollment for prostate cancer, recommendations to improve outreach and education, including best practices for outreach to African-American men and other high-risk men. (h) Meetings The Coordinating Committee shall meet at the request of the Secretary not less 3 times each year. (i) FACA Except as provided in this section, the Federal Advisory Committee Act (5 U.S.C. App.) shall not apply to the Coordinating Committee. (j) Report (1) Initial report Not later than 1 year after the date of the enactment of this section, the Coordinating Committee shall submit recommendations using the plan under subsection (g) to the following: (A) The Secretary of the Department of Health and Human Services. (B) The Secretary of Defense. (C) The Secretary of Veterans Affairs. (D) The Committees on Energy and Commerce and Appropriations of the House of Representatives. (E) The Committees on Health, Education, Labor, and Pensions and Appropriations of the Senate. (2) Updated reports Not later than 3 years after the date of the enactment of this section, and every 3 years